SDGR Accelerates Hosted Software Transition as Software ACV Grows 10.6% and Operating Expenses Decline

Revenue Mix Shifts as Software Outpaces Drug Discovery Gains

Schrödinger (NASDAQ: SDGR) released its fourth quarter and full-year 2025 financials, highlighting a strategic mix shift as annual contract value (ACV) from software continues to anchor growth. In 2025, total revenue reached $255.9 million, a 23.3% increase on the prior year. Software revenue grew 10.6% to $199.5 million, while software ACV rose to $198.5 million—a narrower but meaningful 4% increase. Drug discovery revenue also expanded, more than doubling from $27.2 million in 2024 to $56.4 million in 2025.

The company’s leadership views the transition toward ratable, hosted software revenue as central to achieving more stable and predictable results. Accelerated hosted deployments, which accounted for 23% of total software revenue in 2025 (up from 20% in 2024), are expected to mitigate revenue timing volatility going forward.

Cost Controls and Cash Reserves Support Growth Transition

Operating expenses declined by 9.3% to $309.5 million, with R&D spend scaling down from the prior year. This discipline, combined with robust cash reserves of $402.3 million, provides Schrödinger with flexibility as it advances its transition to hosted licensing and invests in next-generation solutions like predictive toxicology and the AI-driven RetroSynth platform.

Net loss for the year narrowed substantially to $103.3 million (from $187.1 million in 2024), while quarterly results flipped to a net income of $32.5 million in Q4, buoyed by gains in equity investments and a strong gross margin of 81% for the software segment. Adjusted EBITDA remains negative but improved significantly, reflecting steady gains toward the firm’s ambition of reaching positive adjusted EBITDA by the end of 2028.

Key Performance Indicators Signal Momentum Among Top Customers

Software customer engagement remains robust, with commercial annual contract value exceeding $1 million per customer up 16.3% to $3.9 million. The top 20 pharma customers increased their share of ACV by 15.3% to $80.8 million. Customer retention is high: gross dollar retention stood unchanged at 96%, while net dollar retention declined from 113% to 100%, reflecting the company’s ongoing transition and some consolidation among large contracts.

Hosted Licensing Shift Sets Up Margin Expansion by 2028

The company’s 2026 outlook guides for software ACV growth of 10–15% to a range of $218–$228 million, with drug discovery revenue expected between $55–$65 million. Operationally, expenses are forecast to remain below 2025 levels. Schrödinger expects hosted contracts to make up the majority of its software revenue by 2028, enabling margin percentages to return to the high 70s while normalizing revenue recognition.

• 2028 target: Durable software ACV growth of 10–15% annually.
• Gross margin: Return software gross margins to the high 70s percent.
• Adjusted EBITDA: Achieve positive adjusted EBITDA by year-end 2028.
• Drug discovery revenue: $50 million annual target, subject to milestone timing.

Platform Innovation and Pipelines Drive Growth Narrative

Recent platform launches such as RetroSynth—aimed at improving molecule synthesis using AI—and partnerships with pharma innovators like Lilly TuneLab and Manas AI reinforce Schrödinger’s positioning at the frontier of computational drug discovery. The company now counts 16 active programs eligible for future royalties and over 20 partners since 2018, with a robust pipeline of clinical-stage programs. Notable clinical developments by co-founded ventures and strategic partners (such as Structure Therapeutics and Takeda/Nimbus) position Schrödinger to capture upside from external milestones as well.

Bottom Line: Financial Flexibility Supports Long-Term Strategy

With a leaner expense base, growing ACV, and strong recurring cash flow, Schrödinger is well equipped to weather short-term revenue recognition headwinds as it accelerates the adoption of hosted licenses. Investors tracking software platform transitions and biotech innovation may find SDGR’s margin improvement path and royalty-eligible pipeline especially worth monitoring in the quarters ahead.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI